Lancet[journal] 检索结果

861. Department of Error.

来源: Lancet. 2025年406卷10505期810页

862. Department of Error.

来源: Lancet. 2025年406卷10505期810页

863. Progress towards global nutrition targets and future directions.

作者: Qi Chen.;Xiaowei Tang.
来源: Lancet. 2025年406卷10505期809页

864. Progress towards global nutrition targets and future directions - Authors' reply.

作者: Robert Reiner.;Nicholas J Kassebaum.
来源: Lancet. 2025年406卷10505期809-810页

865. Progress towards global nutrition targets and future directions.

作者: Michael Bode.;Natalie Carvalho.;Sumie Leung.;Sant-Rayn Pasricha.
来源: Lancet. 2025年406卷10505期808页

866. INTERLACE: not a new standard for cervical cancer chemoradiation - Authors' reply.

作者: Mary McCormack.;Gemma Eminowicz.;Simran Vaja.;Allan Hackshaw.;Jonathan Ledermann.
来源: Lancet. 2025年406卷10505期807页

867. Progress towards global nutrition targets and future directions.

作者: Jianzhong Yin.;Qiong Meng.;Yuemei Feng.
来源: Lancet. 2025年406卷10505期807-808页

868. INTERLACE: not a new standard for cervical cancer chemoradiation.

作者: Primoz Petric.;Jacob Christian Lindegaard.;Maximillian Paul Schmid.;Ina Jürgenliemk-Schulz.;Umesh Mahantshetty.;Christian Kirisits.;Richard Pötter.
来源: Lancet. 2025年406卷10505期806-807页

869. Measles in 2025-lessons from the USA, Canada, and Australia.

作者: Peter Bruce McIntyre.
来源: Lancet. 2025年406卷10505期805-806页

870. Humility and curiosity in human-AI systems for health care.

作者: Sebastián Andrés Cajas Ordoñez.;Maximin Lange.;Torleif Markussen Lunde.;Mackenzie J Meni.;Anna E Premo.
来源: Lancet. 2025年406卷10505期804-805页

871. Excess weight loss and safety outcomes from the randomised SADISLEEVE trial.

作者: Daryl Kai Ann Chia.;Asim Shabbir.
来源: Lancet. 2025年406卷10505期787-789页

872. The role of community health workers in promoting health equity.

作者: Nancy Byatt.;Clevanne Julce.
来源: Lancet. 2025年406卷10505期785-787页

873. Antisense oligonucleotide-directed liver therapy: a new tool in the MASH armamentarium?

作者: Paul N Brennan.;John F Dillon.
来源: Lancet. 2025年406卷10505期783-784页

874. RFK Jr and MAHA: dangerous, emboldened, and escalating.

作者: The Lancet.
来源: Lancet. 2025年406卷10505期779页

875. Safety and efficacy of steroidal mineralocorticoid receptor antagonists in patients with kidney failure requiring dialysis: a systematic review and meta-analysis of randomised controlled trials.

作者: Lonnie Pyne.;Patrick Rossignol.;Cameron Giles.;Mats Junek.;Patrick B Mark.;Martin Gallagher.;Janak R de Zoysa.;P J Devereaux.;Michael Walsh.
来源: Lancet. 2025年406卷10505期811-820页

Mineralocorticoid receptor antagonists can prevent cardiovascular events in patients with heart failure and non-severe chronic kidney disease, but their effects in patients with kidney failure requiring dialysis are uncertain. We aimed to assess the efficacy and safety of mineralocorticoid receptor antagonists in this patient population.

876. Clarity in gender-inclusive language in reproductive health care.

作者: Sally Pezaro.;John Pendleton.;Isaac Samuels.
来源: Lancet. 2025年406卷10505期804页

877. Is Gaza still a place for newborn life?

作者: Bilal Irfan.;Shaymaa Abuhaiba.;Meran Abusultan.;Othman Nassar.
来源: Lancet. 2025年406卷10505期803页

878. Requiem for mineralocorticoid blockade in maintenance dialysis.

作者: Qandeel H Soomro.;David M Charytan.
来源: Lancet. 2025年406卷10505期780-782页

879. Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial.

作者: Mazen Noureddin.;Juan P Frias.;Guy W Neff.;K Jean Lucas.;Cynthia Behling.;Pierre Bedossa.;Julie Dubourg.;Doreen Chan.;Mark Burch.;Erica Fong.;Brittany de Temple.;Matt Minerva.;Kim Barrett.;Reshma Shringarpure.;Erik J Tillman.;Timothy Rolph.;Andrew Cheng.;Kitty Yale.
来源: Lancet. 2025年406卷10504期719-730页

Efruxifermin is a bivalent fibroblast growth factor 21 analogue in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). This trial aimed to prospectively assess the safety and efficacy of efruxifermin administration for 96 weeks in individuals with MASH and moderate (stage 2; F2) or severe (stage 3; F3) fibrosis.

880. Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysis.

作者: Patrick Rossignol.;Faiez Zannad.;Ziad Massy.;Michel Azizi.;Fatima Chorfa.;Julien Coadic.;João Pedro Ferreira.;Francisca Saraiva.;Dominique Mottier.;Francis Guillemin.;Willy Ngueyon Sime.;Sanae Bouali.;Bénédicte Rossignol.;Joëlle Nortier.;Isabelle Simon.;Christophe Robino.;Manuela Davin.;Pierre M Bataille.;François Chantrel.;Nelly Castin.;Vincent Esnault.;Isabelle Kazes.;Thierry Hannedouche.;Nassim Kamar.;Jean-Michel Achard.;Caroline Fenerol.;Carine Achard-Hottelart.;Yves Dimitrov.;Nicolas Girerd.;Delphine Maucort-Boulch.;Luc Frimat.; .
来源: Lancet. 2025年406卷10504期705-718页

No pharmacological therapy has been shown with certainty to improve the cardiovascular prognosis in patients with kidney failure on chronic haemodialysis. We aimed to investigate the effects of the steroidal mineralocorticoid receptor antagonist spironolactone on cardiovascular outcomes in patients on haemodialysis who are at high risk of cardiovascular events.

结果排序

文献格式

出版时间

出版类型

出版语言